Gilde seeking value in bear market with focus on POC, ‘dynamic’ bets on public biotechs

Despite biotech entering its third year of a downturn in the public markets, blue-chip VCs are still attracting LP money and raising their largest-ever funds, with Gilde the latest example.

Gilde Healthcare’s Arthur Franken and Joep Muijrers told BioCentury the strategy for the new fund will remain focused on therapeutics, digital medicine and medtech across Europe and North America, but its sweet spot will be making investments that generate clinical proof of concept...